21 Ha’arba’a Street
337 articles with RedHill Biopharma
RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting
RedHill Biopharma Ltd. announced that two oral presentations and two posters on two of the Company’s leading drug candidates, RHB-1051 and RHB-104 will be presented at the American College of Gastroenterology 2019 Annual Scientific Meeting, being held October 25-30, in San Antonio, Texas.
We round out the month of October and start the month of November with four PDUFA dates on the U.S. Food and Drug Administration’s calendar. Here’s a look.
RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO
RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V.
10/17/2019Companies from across the globe provide business and pipeline updates.
6/13/2019Companies from across the globe share business and pipeline updates.
5/24/2019Biopharma companies from across the globe strengthen their leadership teams with key executive appointments.
Companies from across the globe provide updates to their pipelines and businesses, with news from BioNTech, Mologic, Akcea, RedHill, and more.
2/22/2019Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more.
After enduring a deluge from multiple hurricanes earlier this year, the Carolinas are about to be flooded with something else far more preferable – jobs. Pharma companies are hiring for hundreds of positions, according to reports.
RedHill Biopharma Announces Advancement to Second Stage of Phase IIa Study with YELIVA® for Cholangiocarcinoma
The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous received other treatments
RedHill Biopharma Ltd. announced the closing of its previously announced underwritten offering of 4,166,667 American Depositary Shares
RedHill Biopharma Elaborates on Its Announced Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease
RedHill Biopharma Ltd. today elaborated on the previously announced positive top-line results from the first Phase III study with orally-administered RHB-104 for Crohn’s disease (the MAP US study).
RedHill Biopharma, with offices in Tel Aviv, Israel and Raleigh, North Carolina, announced positive topline data from its first Phase III trial of RHB-104 for Crohn’s disease. It met all primary endpoint and key secondary endpoints.
RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) and an Intention to Grant from the European Patent Office (EPO) for two new patents covering RHB-104, expected to be valid until at least February 5, 2029, once granted.
RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®
RedHill has been grantedthe exclusive right to co-promote Mytesi® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by Napo Pharmaceuticals, a subsidiary of Jaguar Health
RedHill Biopharma to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call on February 22, 2018
To participate in the conference call, please dial one of the following numbers 15 minutes prior to the start of the call:
RedHill Biopharma and Express Scripts Subsidiary Inside Rx Add EnteraGam to Savings Program for Uninsured or Underinsured Patients
This program allows RedHill to provide a discount on EnteraGam directly to eligible patients who are uninsured or underinsured.
The company confirmed that the Phase II study with BEKINDA 12 mg successfully met its primary endpoint.
Cash balance at the end of 2017 is expected to be approximately $45 million, with no debt.
Gross proceeds from the sale of the ADSs by RedHill before underwriting discounts and commissions and other offering expenses were approximately $22.5 million.